Topical Gene Therapy for Epidermolysis Bullosa

  • Phimister, Elizabeth G. Ph.D.; Editor
  • Payne, Aimee S. M.D., Ph.D.

  • From the Department of Dermatology, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia.

New England Journal of Medicine 387(24):p 2281-2284, December 15, 2022. | DOI: 10.1056/NEJMe2213203

Corresponding Article

Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa

  • Guide, Shireen V. M.D.
  • Gonzalez, Mercedes E. M.D.
  • Bağcı, I. Sinem M.D.
  • Agostini, Brittani B.S.N.
  • Chen, Hubert M.D.
  • Feeney, Gloria B.S.
  • Steimer, Molly B.S.
  • Kapadia, Binoy B.S.
  • Sridhar, Kunju Ph.D.
  • Quesada Sanchez, Lori B.S.
  • Gonzalez, Franshesca B.S.
  • Van Ligten, Matthew B.S.
  • Parry, Trevor J. Ph.D.
  • Chitra, Surya Ph.D.
  • Kammerman, Lisa A. Ph.D.
  • Krishnan, Suma M.S.
  • Marinkovich, M. Peter M.D.
New England Journal of Medicine 387(24):p 2211-2219, December 15, 2022. | DOI: 10.1056/NEJMoa2206663

Corresponding Article

The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

  • Schaffer, David V. Ph.D.
New England Journal of Medicine 387(24):p 2279-2280, December 15, 2022. | DOI: 10.1056/NEJMe2212899
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF